Semaglutide syringe size: what Wegovy's pre-filled pen actually contains

You've just searched 'semaglutide syringe size', here's what's actually in the box

Imagine you've been prescribed Wegovy and the pen arrives. You open the box expecting something resembling an insulin syringe: a clear barrel, dose markings, a plunger you draw back. What you find instead is a small auto-injector pen that looks closer to an EpiPen than anything from a GP's phlebotomy drawer. The needle is hidden inside and covered by a cap. You dial nothing. You press the pen against clean skin, press the button, and the device delivers the dose. That's the whole physical act.

This matters because a common misconception circulates online: that people at home are drawing semaglutide from multi-dose vials into insulin syringes, choosing their own needle gauge and volume. That practice describes unlicensed, compounded semaglutide, not the Wegovy product approved by the MHRA for weight management in UK adults. The two are not interchangeable, legally or clinically. Our page on semaglutide's pre-filled delivery format covers this distinction in more detail.

The pre-filled pen eliminates the variables that make syringe size a genuine question for, say, insulin users: there is no volume to calculate, no gauge to select for a given viscosity, no dead-space loss to account for. The manufacturer has resolved all of that inside the device. What remains for the patient is technique (angle, site rotation, holding the pen in place) and that is covered in the Patient Information Leaflet supplied with every pen and by the prescribing team.

Why the needle gauge still matters, even when you don't choose it

Even though Wegovy's pen comes ready to use, the needle specification is worth understanding. Subcutaneous injection needles used in these devices are very fine, typically around 32 gauge and 4 to 8 mm in length. That combination is chosen specifically to minimise discomfort and reach the subcutaneous fat layer without going deeper into muscle. The shorter the needle, the less likely an injection into the abdomen or thigh is to cause more than a brief sting.

People who have only ever encountered intramuscular injections (vaccines, for instance) sometimes expect semaglutide to be administered with a longer, wider needle. It isn't. The gauge and length are selected for the subcutaneous route, and the device handles insertion angle automatically in most pen models. If you use the Wegovy pen, the needle is factory-fitted and single-use: one injection, one needle, then the entire pen is disposed of in a sharps container.

Injection site matters as much as needle spec. The abdomen (at least 5 cm from the navel), the front of the thigh, and the outer upper arm are all licensed sites. Rotating between them each week reduces the risk of localised skin changes, something worth discussing with your prescribing team if you notice any thickening or tenderness.

The Wegovy 7.2 mg pen: a different format for a higher dose

In April 2026, the MHRA approved a dedicated single-dose 7.2 mg semaglutide pen, a higher maintenance dose than the standard 2.4 mg. This pen has its own auto-dosing mechanism, a built-in covered needle that locks after use, and is intended for once-weekly subcutaneous injection in adults with a BMI of 30 or above, following the same titration pathway from 0.25 mg upward, a starting dose with its own delivery considerations. Trials reported approximately 20.7% average weight loss over 72 weeks at this dose, narrowing the gap with tirzepatide results.

The physical format remains a pre-filled pen, not a syringe. The MHRA's announcement of the 7.2 mg pen approval sets out the licensed indication. If you're considering treatment at this dose level, that's a conversation for a prescriber, not something to self-select. Our page on semaglutide sizing covers how dose steps work across the full escalation schedule.

One practical note: a higher-dose pen does not mean a larger injection volume visible to the patient. The delivered volume is still small (typically a fraction of a millilitre) and the pen conceals it entirely. The experience of using a 7.2 mg pen is not meaningfully different from using a 2.4 mg pen in terms of what you see and feel.

Licensed Wegovy versus unlicensed compounded semaglutide: why this distinction is worth making

Some people searching for syringe sizes are trying to understand compounded semaglutide: a preparation mixed in a pharmacy, sometimes supplied as a vial with separate syringes. This is not the same product as Wegovy. Compounded semaglutide does not carry UK marketing authorisation for weight management. The MHRA has warned repeatedly about unlicensed semaglutide products, including injectable preparations sold without a prescription, with some seizures involving products found to be unsafe or counterfeit.

A legitimate UK supply chain for semaglutide weight management means Wegovy: MHRA-approved, from an authorised manufacturer, dispensed following a valid prescription assessed by a GPhC-registered prescriber. For context on what to look for and what to avoid, our semaglutide overview page covers the licensing landscape. If cost is a factor in your search, our guide to Wegovy pricing in the UK sets out what private treatment actually costs and what drives price variation across providers.

The device format, the supply route and the clinical oversight are all part of the same picture. Getting treatment through a GPhC-registered pharmacy with a proper prescriber review is not a formality, it is the safeguard that makes the pen in your hand the right medicine at the right dose.